Aster and Blackstone-backed Quality Care to merge and create hospital chains in India
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
New research labs and process development services to enable next generation therapeutics
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Modernization and supply chain diversity drive new growth
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Subscribe To Our Newsletter & Stay Updated